title: Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations.
abstract: Eight different protocols were compared for their ability to raise protection against immunodeficiency virus challenges in rhesus macaques. The most promising containment of challenge infections was achieved by intradermal DNA priming followed by recombinant fowl pox virus booster immunizations. This containment did not require neutralizing antibody and was active for a series of challenges ending with a highly virulent virus with a primary isolate envelope heterologous to the immunizing strain.
authors.affiliation: Yerkes Regional Primate Research Center, Atlanta, Georgia 30329, USA.
authors.forename: H L
authors.initials: HL
authors.lastname: Robinson
authors.forename: D C
authors.initials: DC
authors.lastname: Montefiori
authors.forename: R P
authors.initials: RP
authors.lastname: Johnson
authors.forename: K H
authors.initials: KH
authors.lastname: Manson
authors.forename: M L
authors.initials: ML
authors.lastname: Kalish
authors.forename: J D
authors.initials: JD
authors.lastname: Lifson
authors.forename: T A
authors.initials: TA
authors.lastname: Rizvi
authors.forename: S
authors.initials: S
authors.lastname: Lu
authors.forename: S L
authors.initials: SL
authors.lastname: Hu
authors.forename: G P
authors.initials: GP
authors.lastname: Mazzara
authors.forename: D L
authors.initials: DL
authors.lastname: Panicali
authors.forename: J G
authors.initials: JG
authors.lastname: Herndon
authors.forename: R
authors.initials: R
authors.lastname: Glickman
authors.forename: M A
authors.initials: MA
authors.lastname: Candido
authors.forename: S L
authors.initials: SL
authors.lastname: Lydy
authors.forename: M S
authors.initials: MS
authors.lastname: Wyand
authors.forename: H M
authors.initials: HM
authors.lastname: McClure
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005587:Fowlpox virus / Q000235:genetics; D007271:Injections, Intradermal; D016180:Lentivirus Infections / Q000276:immunology* / Q000517:prevention & control*; D008251:Macaca; D009500:Neutralization Tests; D012367:RNA, Viral / Q000097:blood; D013602:T-Lymphocytes, Cytotoxic; D014611:Vaccination; D019444:Vaccines, DNA / Q000627:therapeutic use*; D014765:Viral Vaccines / Q000627:therapeutic use*
chemical_list: D000914:Antibodies, Viral; D012367:RNA, Viral; D019444:Vaccines, DNA; D014765:Viral Vaccines